Expert video report on sarcomas

ASCO 2019

Speaker: Silvia Stacchiotti

S. Stacchiotti reports from ASCO 2019 on study results presented in soft tissue sarcomas (STS). She explains the heterogeneity of STS and illustrates, using the example of olaratumab, why large trials sometimes don't confirm the promising results obtained in smaller studies in specific subtypes. She also reports on positive results with an EZH2 inhibitor in epithelioid sarcoma.

Abstract discussed:

  • LBA3 / ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS).
  • Abstract 11003 / Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950).